This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acorda To Present New Research On Novel Multiple Sclerosis And Epilepsy Therapies At American Academy Of Neurology 65th Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq:  ACOR) will present new research data at the 65 th American Academy of Neurology Annual Meeting on AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg, an FDA-approved therapy indicated to improve walking in people with multiple sclerosis, and Diazepam Nasal Spray, an investigational therapy for the treatment of cluster seizures, also known as acute repetitive seizures, in people with epilepsy.

“Acorda is focused on improving the lives of people with neurological disorders. We currently are developing seven therapies for a range of conditions, including multiple sclerosis, epilepsy and spinal cord injury,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “Our presentations at AAN include new studies on AMPYRA and the first clinical data presented on Diazepam Nasal Spray. These studies have increased our understanding of the potential roles these therapies could have in addressing the urgent needs of patients with these conditions.”

Data being presented on Acorda-developed therapies at the AAN annual meeting include:

  • Changes in Gait, Walking, and Balance Parameters After Withdrawal and Re-initiation of Dalfampridine Extended Release Tablets in Patients with Multiple Sclerosis: Results from the STEADY Study – P04.103 being presented Wednesday, March 20 th, 7:30am – 12:00pm
  • Safety and Efficacy of 5mg and 10mg Dalfampridine Extended Release Tablets in Patients with Multiple Sclerosis: First Results from a Double-Blind, Placebo-Controlled Trial – P04.096 being presented Wednesday, March 20 th, 7:30am – 12:00pm
  • Effects of 5mg and 10mg Dalfampridine Extended Release Tablets on 6-Minute Walk Distance in People with Multiple Sclerosis: A Subgroup Analysis of a Double-Blind, Placebo-Controlled Trial – S01.007 being presented Tuesday, March 19 th at 2:30pm
  • Assessment of Pharmacokinetic Linearity and Relative Bioavailability of a Nasal Diazepam Formulation Compared with Diazepam Rectal Gel In Healthy Adult Subjects – P02.214 being presented Tuesday, March 19 th, 7:30am – 12:00pm

More detailed information on scientific sessions and data presentations at the AAN annual meeting can be found on the conference website (

Important Safety Information

Do not take AMPYRA if you have ever had a seizure or have certain types of kidney problems.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs